Eyre et al (medrxiv.org/content/10.110…) is a tour-de-force. Bravo!
- traced 150k contacts from 100k cases (! - NHS👏🏽)
- Pfizer vax'd index cases had ~5x (Alpha) or 3x (Delta) lower odds of spreading (this is beyond protection by preventing the index case to begin with)
🧵 1/6
2/6 - this despite similar cycle thresholds (Ct) in vax'd vs unvax'd index Delta cases, as others have shown
- Pfizer vax'd contacts had 16x (Alpha) or 10x (Delta) lower odds of being infected
- Ct is not infectivity
- Ct is not infectivity
- Ct is not infectivity
- #VaccinesWork
3/6 - they also saw waning, c/w other studies (incl imo the best studies, the post-hoc crossover analyses of mRNA RCTs). Here, they found 1.2x increased odds of transmission "for each doubling of weeks since 14 days after 2nd vax in index cases" (?), & 1.4x increase in contacts.
4/6 - interestingly, though Pfizer worked better than AZ against Delta overall, it also seemed to wane quicker, at least for protecting contacts (p = 0.002). Similar results seen elsewhere w/ J&J (less waning). Seems like support for 6 mo boost of mRNA vax (hopefully just x1)?
5/6 - contacts of asymptomatic index cases were less likely to test +, but this was more true for Alpha (>3x lower odds) than Delta (<2x lower odds)
- vax lowered measured VL in Alpha but not Delta cases
- higher VL transmitted more than lower VL, but vax helped at any VL (Ct)
6/6 Summary of a super-rich paper: Delta sucks, vaccines work less well against it that Alpha and wane a bit, but they still work really, really well (10x lower odds of being infected, 3x lower odds of spreading if infected).
Btw, sometimes when I describe papers as "super-rich", it's code for "complicated".
This preprint isn't that. It's clearly written, & w/in limits of my ability to assess, very well done. It's super-rich b/c they traced 100,000 cases to 150,000 contacts FFS!!! Well worth a read.
Important point raised by @CrazyTalk : the odds ratios I cited throughout this thread come from Table 1 and are basically maximal activity (estimated at 14d post-dose 2); they wane from there.
Yet another good point (h/t @MarvinH2_G2): since this is a UK study, it probably reflects longer dose interval b/w Pfizer doses. No controlled data I'm aware of on how this would matter, but I might expect more waning w/ the standard 3 wk interval.
My takeaways:
- vaccines protect you from getting infected (but aren't perfect)
- if infected, vaccines reduce risk of transmitting to others (but aren't perfect - less good at this)
- both wane
- they're the most important intervention, but not the only needed w/ Delta raging
Anyway, glad ppl seem to be enjoying this thread. I've learned a lot from the discussion already, but I have to get to work on 5 grants due this month (that's at least 2 too many!!!)
Please, read the preprint! Layers of nuance I had to simplify #onhere
At the risk of shouting into the void, 🧵 on papers from 2020 that most changed how I think abt COVID, as an ID physician-scientist. 280-char summaries + URLs for each. Thx to all authors & apologies for any omissions; this list is unofficial, personal, idiosyncratic, & LONG. 1/
2/ Early summary of 72,314 (hospitalized) cases from Chinese CDC, broken down by mild vs severe vs critical, early hint at CFR (overestimated b/c mild cases undersampled), & sharply age-dependent mortality. Also, risk to HCWs. Fig 1 (epidemic curve) key.
3/ Another inpt obs cohort study from China 🙏🏽. Fig 2 shows prognostic biomarkers (lymphs, D-dimer, IL-6 – not CRP, despite my false memory). Watched (helplessly) a lot of these rise in worsening patients. Still wonder why we ordered so many, so often.
2/8 From the editorial: "A big concern has been test availability, but test accuracy may prove a larger long-term problem."
I disagree w this framing: the two features are in direct tension. If we hold out for "perfectly" sensitive tests, we resign ourselves to less testing.
3/8 Great modeling studies from folks I tagged shows frequency/TAT are MUCH more impt than sensitivity: medrxiv.org/content/10.110…